Analysis of Risk of Recurrence by Subtype in ≤ 1-cm Breast Tumors

Micro-Abstract Triple negative breast cancer (TNBC) is aggressive, and the benefit of adjuvant chemotherapy among women with ≤ 1-cm, lymph node-negative TNBC is unknown. Among 437 women diagnosed with stage T1a-T1bN0 breast cancer from 1997 to 2009, recurrence-free survival did not differ significan...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical breast cancer 2016-06, Vol.16 (3), p.223-231
Hauptverfasser:	Colonna, Sarah V, Higgins, Ashantice K, Alvarez, Joann, Saville, Benjamin R, Lawrence, Julia, Abramson, Vandana G
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Chemotherapy Disease-Free Survival Female Hematology, Oncology and Palliative Medicine HER2 Humans Kaplan-Meier Estimate Middle Aged Neoplasm Recurrence, Local - epidemiology Node negative Obstetrics and Gynecology Proportional Hazards Models Risk Factors Small tumor Triple negative Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - mortality Triple Negative Breast Neoplasms - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Micro-Abstract Triple negative breast cancer (TNBC) is aggressive, and the benefit of adjuvant chemotherapy among women with ≤ 1-cm, lymph node-negative TNBC is unknown. Among 437 women diagnosed with stage T1a-T1bN0 breast cancer from 1997 to 2009, recurrence-free survival did not differ significantly between those with TNBC and those with estrogen receptor-positive breast cancer (hazard ratio [HR], 0.33; 95% confidence interval [CI], 0.10-1.04; P = .058), and adjuvant chemotherapy had no significant effect (HR, 0.6; 95% CI, 0.2-1.9; P = .392).
ISSN:	1526-8209 1938-0666
DOI:	10.1016/j.clbc.2015.10.001